Henlius’ Trastuzumab Approved In China
Becomes First China-Developed mAb Biosimilar Approved In Both China And EU
Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.
You may also be interested in...
Henlius has announced plans to seeing its sales shoot up in 2020 based on three new launches.
After receiving approval from the Chinese regulatory body for rituximab and trastuzumab, Shanghai Henlius Biotech has now received approval for its HLX03 adalimumab biosimilar rival to Humira. The company has partnered with Wanbang Biopharma for commercialization of HLX03 in China.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.